CD274 and esophageal cancer: With the approvals of PD-1/PD-L1 inhibitors in esophageal cancer, clinicians are now faced with substantial new questions concerning effectiveness, safety, and optimal treatment patterns in a broader patient population we deal with in daily life, including fragile patients with older age and those with poor performance status that are generally excluded from pivotal trials.